GlassScriptPhysician profile
Omoleagho Garuba
NPI 1366144057
$2,031.28
in general payments reported to CMS, 2019-2025
22 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $149 · 2024: $783 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $330.25 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $255.01 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $160.70 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $159.15 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $157.97 | 2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $155.84 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $145.99 | 2024-2025 | Veozah |
| Pfizer INC. | $107.60 | 2023-2025 | |
| Abbvie INC. | $88.07 | 2023-2025 | |
| Lilly USA, LLC | $81.49 | 2024-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $69.31 | 2025 | Bodyguardian |
| Janssen Pharmaceuticals, INC | $48.50 | 2023 | Xarelto |
| Axsome Therapeutics, INC. | $43.87 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.63 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $35.00 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $33.66 | 2024 | Azstarys |
| Shield Therapeutics INC | $29.75 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $20.98 | 2025 | Neffy |
| Lundbeck LLC | $20.02 | 2025 | Rexulti |
| Becton, Dickinson and Company | $17.34 | 2024 | Bd Onclarity |
| Glaxosmithkline, LLC. | $16.34 | 2025 | Arexvy, Shingrix |
| Dexcom, INC. | $15.81 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omoleagho Garuba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.